Afinitor is currently paid for by provincial drug plans for patients with well-or moderately differentiated neuroendocrine tumours of pancreatic origin (pNET), in patients with unresectable, locally advanced or metastatic disease.

In 2016 an application was put forward to extend the indication for Afinitor to include unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NET) of gastrointestinal or lung origin in adults with progressive disease.  A positive pCODR recommendation was received in December 2016 and the next phase entered into, which is a negotiation with the Pan-Canadian Pharmaceutical Alliance (pCPA).  After negotiation with the pCPA has concluded, Afinitor should be listed on provincial drug plans across Canada allowing for reimbursement for lung and GI NET patients.

Until such time as the listing takes place, if any lung or GI NET patients are experiencing issues gaining paid access to Afinitor please reach out to